Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10,734.00
Bid: 10,734.00
Ask: 10,738.00
Change: -8.00 (-0.07%)
Spread: 4.00 (0.037%)
Open: 10,756.00
High: 10,780.00
Low: 10,730.00
Prev. Close: 10,742.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Positive Results For AstraZeneca Drugs Imfinzi And Lynparza

Fri, 18th Sep 2020 09:21

(Alliance News) - AstraZeneca PLC on Friday said updated results from its Pacific phase 3 trial of Imfinzi showed a sustained and clinically meaningful improvement in overall survival and progression-free survival in lung cancer.

The trial was of patients with unresectable, stage 3 non-small cell lung cancer who had not progressed after concurrent chemoradiation therapy. One in three patients with non-small cell lung cancer are diagnosed at stage 3, at which point most tumours are unresectable - meaning they cannot be removed with surgery.

Before Imfinzi in this setting, there have been no new treatments past chemoradiation therapy in decades.

Results from the updated post-hoc analyses showed an estimated four-year survival rate with Imfinzi of 50% compared to 36% with placebo after chemoradiation therapy. Median overall survival was 47.5 months for Imfinzi and 29.1 months with placebo.

At the maximum treatment course of one year, around 35% of patients treated with the drug had not progressed four years after enrolment compared to 20% with placebo.

Jose Baselga, executive vice president of Oncology R&D as Astra, said: "These unprecedented four-year results reinforce Imfinzi as the established standard of care in unresectable, stage 3 non-small cell lung cancer and set a new survival benchmark in a setting where cure is the treatment goal. With data also at ESMO for Caspian in small cell lung cancer patients, Imfinzi continues to deliver impressive long-term benefits across different types of lung cancer."

In the primary analysis of Pacific phase 3, the most comment adverse events among patients were cough, which 35% experienced compared to 25% with the placebo; fatigue, 24% versus 21%; dyspnoea, 22% versus 24%; and radiation pneumonitis, 20% versus 16% with placebo. A grade 3 or 4 adverse event occurred in 31% of patients treated with Imfinzi compared to 26% with placebo. A total of 15% of patients discontinued Imfinzi treatment due to adverse events compared to 9.8% with placebo.

Astra also posted results from the Caspian phase 3 trial exploratory subgroup analyses in extensive-stage small cell lung cancer. These subgroup analyses were conducted to characterise patients deriving long-term benefit.

Over three times as many patients treated with Imfinzi plus chemotherapy were alive and progression-free for a year or more versus chemo alone, 17% compared to 4.5%.

In all treatment arms, those patients who were progression free at 1 year had a 75% chance of being alive at 2 years. In comparison, those patients whose disease did progress within a year had a 10% change of being alive at 2 years.

Caspian met its primary endpoint of overall survival in 2019, reducing risk of death by 27% in extensive-stage small cell lung cancer.

Separately on Friday, Astra posted five-year data from its Solo-1 phase 3 trial of another cancer drug, Lynparza. This is the longest follow-up analysis for any PARP inhibitor in the first-line maintenance setting.

Data showed that Lynparza improved median time patients lived without disease progression to more than 4.5 years in BRCA-mutated advanced ovarian cancer, compared to just over 1 year with placebo.

BRCA mutations are associated with certain cancers, with around 22% of patients with ovarian cancer having a BRCA1/2 mutation.

PARP is an enzyme in cells that helps to repair damaged DNA, and so inhibiting this enzyme prevents cancer cells from repairing themselves.

The five-year follow-up showed that Lynparza reduced risk of disease progression or death by 67% to a median of 56.0 months compared to 13.8 months with placebo. At five years, 48% of patients treated with the drug remained free from disease progression compared to 21% with placebo. The median duration of Lynparza treatment was 24.6 months compared to 13.9 months with placebo.

Baselga said: "Once a patient's ovarian cancer recurs, it historically has been incurable. Even at an advanced stage, we have shown that maintenance treatment with Lynparza can help patients achieve sustained remission. Today's results further underline the critical importance of identifying a patient's biomarker status at the time of diagnosis to offer a treatment that may help delay disease progression."

Astra is developing Lynparza with Kenilworth, New Jersey-based drug maker Merck & Co Inc as part of a strategic oncology collaboration.

Shares in Astra were up 0.8% at 8,718.00 pence in London on Friday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.